Autoimmune Epilepsy

 

 Permissions and Reprints

Abstract

Seizures are recognized as a common manifestation of autoimmune limbic encephalitis and multifocal paraneoplastic disorders, but accumulating evidence supports an autoimmune basis for seizures in the absence of syndromic manifestations of encephalitis. Autoimmune encephalitis and epilepsy have been linked to neural-specific autoantibodies targeting both intracellular and plasma membrane antigens. The detection of these antibodies can serve as a diagnostic marker directing physicians toward specific cancers and can assist in therapeutic decision-making, but are not necessary to establish the diagnosis. Response to an immunotherapy trial can support the diagnosis and help establish prognosis. Early recognition is important because expedited diagnosis can facilitate recovery. In this review, the authors summarize the clinical presentation, pathophysiology, and management of autoimmune epilepsies for which neural antigen-specific autoantibodies serve as diagnostic aids.

• References

• 1 McKeon A, Pittock SJ. Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011; 122 (4) 381-400
  CrossrefPubMedGoogle Scholar
• 2 Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10 (8) 759-772
  CrossrefPubMedGoogle Scholar
• 3 Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77 (2) 179-189
  CrossrefPubMedGoogle Scholar
• 4 Wilkinson PC, Zeromski J. Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. Brain 1965; 88 (3) 529-583
  CrossrefPubMedGoogle Scholar
• 5 Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349 (16) 1543-1554
  CrossrefPubMedGoogle Scholar
• 6 Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4 (11) 1321-1324
  CrossrefPubMedGoogle Scholar
• 7 Tanaka M, Tanaka K, Tokiguchi S, Shinozawa K, Tsuji S. Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody. J Neurol Sci 1999; 168 (1) 28-31
  CrossrefPubMedGoogle Scholar
• 8 Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 2005; 252 (1) (Suppl. 01) I19-I25
  CrossrefPubMedGoogle Scholar
• 9 McKeon A, Martinez-Hernandez E, Lancaster E , et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013; 70 (1) 44-50
  CrossrefPubMedGoogle Scholar
• 10 Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011; 365 (10) 919-926
  CrossrefPubMedGoogle Scholar
• 11 Low NL. Infantile spasms with mental retardation. II. Treatment with cortisone and adrenocorticotropin. Pediatrics 1958; 22 (6) 1165-1169
  PubMedGoogle Scholar
• 12 Sinclair DB. Prednisone therapy in pediatric epilepsy. Pediatr Neurol 2003; 28 (3) 194-198
  CrossrefPubMedGoogle Scholar
• 13 Sinclair DB, Snyder TJ. Corticosteroids for the treatment of Landau-Kleffner syndrome and continuous spike-wave discharge during sleep. Pediatr Neurol 2005; 32 (5) 300-306
  CrossrefPubMedGoogle Scholar
• 14 Rasmussen T, Olszewski J, Lloydsmith D. Focal seizures due to chronic localized encephalitis. Neurology 1958; 8 (6) 435-445
  CrossrefPubMedGoogle Scholar
• 15 Bien CG, Granata T, Antozzi C , et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005; 128 (Pt 3) 454-471
  CrossrefPubMedGoogle Scholar
• 16 Heida JG, Moshé SL, Pittman QJ. The role of interleukin-1beta in febrile seizures. Brain Dev 2009; 31 (5) 388-393
  CrossrefPubMedGoogle Scholar
• 17 Ong MS, Kohane IS, Cai T, Gorman MP, Mandl KD. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol 2014; 71 (5) 569-574
  CrossrefPubMedGoogle Scholar
• 18 Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005; 46 (11) 1724-1743
  CrossrefPubMedGoogle Scholar
• 19 Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7 (1) 31-40
  CrossrefPubMedGoogle Scholar
• 20 Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123 (Pt 7) 1481-1494
  CrossrefPubMedGoogle Scholar
• 21 Majoie HJ, de Baets M, Renier W, Lang B, Vincent A. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res 2006; 71 (2-3) 135-141
  CrossrefPubMedGoogle Scholar
• 22 Barajas RF, Collins DE, Cha S, Geschwind MD. Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia 2010; 51 (3) 473-477
  CrossrefPubMedGoogle Scholar
• 23 Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10 (1) 63-74
  Google Scholar
• 24 Lai M, Hughes EG, Peng X , et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65 (4) 424-434
  CrossrefPubMedGoogle Scholar
• 25 Lancaster E, Lai M, Peng X , et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9 (1) 67-76
  CrossrefPubMedGoogle Scholar
• 26 Lancaster E, Martinez-Hernandez E, Titulaer MJ , et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011; 77 (18) 1698-1701
  CrossrefPubMedGoogle Scholar
• 27 Peltola J, Kulmala P, Isojärvi J , et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000; 55 (1) 46-50
  CrossrefPubMedGoogle Scholar
• 28 Quek AM, Britton JW, McKeon A , et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69 (5) 582-593
  CrossrefPubMedGoogle Scholar
• 29 Liimatainen S, Peltola M, Sabater L , et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 2010; 51 (5) 760-767
  CrossrefPubMedGoogle Scholar
• 30 Toledano M, Britton JW, McKeon A , et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014; 82 (18) 1578-1586
  CrossrefPubMedGoogle Scholar
• 31 Suleiman J, Brilot F, Lang B, Vincent A, Dale RC. Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia 2013; 54 (6) 1036-1045
  CrossrefPubMedGoogle Scholar
• 32 Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 2012; 83 (6) 638-645
  CrossrefPubMedGoogle Scholar
• 33 Iorio R, Lennon VA. Neural antigen-specific autoimmune disorders. Immunol Rev 2012; 248 (1) 104-121
  CrossrefPubMedGoogle Scholar
• 34 Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50 (3) 652-657
  CrossrefPubMedGoogle Scholar
• 35 Roberts WK, Deluca IJ, Thomas A , et al. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009; 119 (7) 2042-2051
  PubMedGoogle Scholar
• 36 Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology 1985; 35 (4) 538-543
  CrossrefPubMedGoogle Scholar
• 37 Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003; 78 (11) 1363-1368
  CrossrefPubMedGoogle Scholar
• 38 Rudzinski LA, Pittock SJ, McKeon A, Lennon VA, Britton JW. Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis. Epilepsy Res 2011; 95 (3) 255-262
  CrossrefPubMedGoogle Scholar
• 39 Dalmau J, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999; 9 (2) 275-284
  PubMedGoogle Scholar
• 40 Jean WC, Dalmau J, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 1994; 44 (1) 140-147
  CrossrefPubMedGoogle Scholar
• 41 Bernal F, Graus F, Pifarré A, Saiz A, Benyahia B, Ribalta T. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol 2002; 103 (5) 509-515
  CrossrefPubMedGoogle Scholar
• 42 Dalmau J, Gultekin SH, Voltz R , et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122 (Pt 1) 27-39
  CrossrefPubMedGoogle Scholar
• 43 Voltz R, Gultekin SH, Rosenfeld MR , et al. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340 (23) 1788-1795
  CrossrefPubMedGoogle Scholar
• 44 Schmidt EF, Strittmatter SM. The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol 2007; 600: 1-11
  PubMedGoogle Scholar
• 45 Arimura N, Hattori A, Kimura T , et al. CRMP-2 directly binds to cytoplasmic dynein and interferes with its activity. J Neurochem 2009; 111 (2) 380-390
  CrossrefPubMedGoogle Scholar
• 46 Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49 (2) 146-154
  CrossrefPubMedGoogle Scholar
• 47 Cross SA, Salomao DR, Parisi JE , et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54 (1) 38-50
  CrossrefPubMedGoogle Scholar
• 48 Lichte B, Veh RW, Meyer HE, Kilimann MW. Amphiphysin, a novel protein associated with synaptic vesicles. EMBO J 1992; 11 (7) 2521-2530
  PubMedGoogle Scholar
• 49 Dropcho EJ. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996; 39 (5) 659-667
  CrossrefPubMedGoogle Scholar
• 50 Pittock SJ, Lucchinetti CF, Parisi JE , et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58 (1) 96-107
  CrossrefPubMedGoogle Scholar
• 51 Wessig C, Klein R, Schneider MF, Toyka KV, Naumann M, Sommer C. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003; 61 (2) 195-198
  CrossrefPubMedGoogle Scholar
• 52 Geis C, Weishaupt A, Hallermann S , et al. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010; 133 (11) 3166-3180
  CrossrefPubMedGoogle Scholar
• 53 Lernmark A. Controlling the controls: GAD65 autoreactive T cells in type 1 diabetes. J Clin Invest 2002; 109 (7) 869-870
  CrossrefPubMedGoogle Scholar
• 54 Solimena M, Folli F, Denis-Donini S , et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 1988; 318 (16) 1012-1020
  CrossrefPubMedGoogle Scholar
• 55 Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322 (22) 1555-1560
  CrossrefPubMedGoogle Scholar
• 56 Moersch FP, Woltman HW. Progressive fluctuating muscular rigidity and spasm (“stiff-man” syndrome); report of a case and some observations in 13 other cases. Proc Staff Meet Mayo Clin 1956; 31 (15) 421-427
  PubMedGoogle Scholar
• 57 Pittock SJ, Yoshikawa H, Ahlskog JE , et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006; 81 (9) 1207-1214
  CrossrefPubMedGoogle Scholar
• 58 Bien CG, Vincent A, Barnett MH , et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 2012; 135 (Pt 5) 1622-1638
  CrossrefPubMedGoogle Scholar
• 59 Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001; 345 (26) 1870-1876
  CrossrefPubMedGoogle Scholar
• 60 Vicari AM, Folli F, Pozza G , et al. Plasmapheresis in the treatment of stiff-man syndrome. N Engl J Med 1989; 320 (22) 1499
  PubMedGoogle Scholar
• 61 Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011; 76 (9) 795-800
  CrossrefPubMedGoogle Scholar
• 62 Benarroch EE. Potassium channels: brief overview and implications in epilepsy. Neurology 2009; 72 (7) 664-669
  CrossrefPubMedGoogle Scholar
• 63 Gutman GA, Chandy KG, Grissmer S , et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 2005; 57 (4) 473-508
  CrossrefPubMedGoogle Scholar
• 64 Ogawa Y, Oses-Prieto J, Kim MY , et al. ADAM22, a Kv1 channel-interacting protein, recruits membrane-associated guanylate kinases to juxtaparanodes of myelinated axons. J Neurosci 2010; 30 (3) 1038-1048
  CrossrefPubMedGoogle Scholar
• 65 Oiso S, Takeda Y, Futagawa T , et al. Contactin-associated protein (Caspr) 2 interacts with carboxypeptidase E in the CNS. J Neurochem 2009; 109 (1) 158-167
  CrossrefPubMedGoogle Scholar
• 66 Lai M, Huijbers MG, Lancaster E , et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9 (8) 776-785
  CrossrefPubMedGoogle Scholar
• 67 Irani SR, Alexander S, Waters P , et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133 (9) 2734-2748
  CrossrefPubMedGoogle Scholar
• 68 Klein CJ, Lennon VA, Aston PA , et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 2013; 70 (2) 229-234
  CrossrefPubMedGoogle Scholar
• 69 Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004; 62 (7) 1177-1182
  CrossrefPubMedGoogle Scholar
• 70 Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008; 70 (20) 1883-1890
  CrossrefPubMedGoogle Scholar
• 71 Vincent A, Buckley C, Schott JM , et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127 (Pt 3) 701-712
  CrossrefPubMedGoogle Scholar
• 72 McKeon A, Marnane M, O'connell M, Stack JP, Kelly PJ, Lynch T. Potassium channel antibody associated encephalopathy presenting with a frontotemporal dementia like syndrome. Arch Neurol 2007; 64 (10) 1528-1530
  CrossrefPubMedGoogle Scholar
• 73 Geschwind MD, Tan KM, Lennon VA , et al. Voltage-gated potassium channel autoimmunity mimicking Creutzfeldt-Jakob disease. Arch Neurol 2008; 65 (10) 1341-1346
  CrossrefPubMedGoogle Scholar
• 74 Flanagan EP, McKeon A, Lennon VA , et al. Autoimmune dementia: clinical course and predictors of immunotherapy response. Mayo Clin Proc 2010; 85 (10) 881-897
  CrossrefPubMedGoogle Scholar
• 75 Klein CJ, Lennon VA, Aston PA, McKeon A, Pittock SJ. Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 2012; 79 (11) 1136-1144
  CrossrefPubMedGoogle Scholar
• 76 Irani SR, Bien CG, Lang B. Autoimmune epilepsies. Curr Opin Neurol 2011; 24 (2) 146-153
  CrossrefPubMedGoogle Scholar
• 77 Irani SR, Stagg CJ, Schott JM , et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 2013; 136 (Pt 10) 3151-3162
  CrossrefPubMedGoogle Scholar
• 78 Diani E, Di Bonaventura C, Mecarelli O , et al. Autosomal dominant lateral temporal epilepsy: absence of mutations in ADAM22 and Kv1 channel genes encoding LGI1-associated proteins. Epilepsy Res 2008; 80 (1) 1-8
  CrossrefPubMedGoogle Scholar
• 79 Nobile C, Michelucci R, Andreazza S, Pasini E, Tosatto SC, Striano P. LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy. Hum Mutat 2009; 30 (4) 530-536
  CrossrefPubMedGoogle Scholar
• 80 Sagane K, Hayakawa K, Kai J , et al. Ataxia and peripheral nerve hypomyelination in ADAM22-deficient mice. BMC Neurosci 2005; 6: 33
  CrossrefPubMedGoogle Scholar
• 81 Baulac S, Ishida S, Mashimo T , et al. A rat model for LGI1-related epilepsies. Hum Mol Genet 2012; 21 (16) 3546-3557
  CrossrefPubMedGoogle Scholar
• 82 Rho JM, Szot P, Tempel BL, Schwartzkroin PA. Developmental seizure susceptibility of kv1.1 potassium channel knockout mice. Dev Neurosci 1999; 21 (3-5) 320-327
  CrossrefPubMedGoogle Scholar
• 83 Strauss KA, Puffenberger EG, Huentelman MJ , et al. Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 2006; 354 (13) 1370-1377
  CrossrefPubMedGoogle Scholar
• 84 Gregor A, Albrecht B, Bader I , et al. Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1. BMC Med Genet 2011; 12 (106) 106
  CrossrefPubMedGoogle Scholar
• 85 Lalic T, Pettingill P, Vincent A, Capogna M. Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia 2011; 52 (1) 121-131
  CrossrefPubMedGoogle Scholar
• 86 Dunstan EJ, Winer JB. Autoimmune limbic encephalitis causing fits, rapidly progressive confusion and hyponatraemia. Age Ageing 2006; 35 (5) 536-537
  CrossrefPubMedGoogle Scholar
• 87 Park DC, Murman DL, Perry KD, Bruch LA. An autopsy case of limbic encephalitis with voltage-gated potassium channel antibodies. Eur J Neurol 2007; 14 (10) e5-e6
  PubMedGoogle Scholar
• 88 Khan NL, Jeffree MA, Good C, Macleod W, Al-Sarraj S. Histopathology of VGKC antibody-associated limbic encephalitis. Neurology 2009; 72 (19) 1703-1705
  CrossrefPubMedGoogle Scholar
• 89 Kotsenas AL, Watson RE, Pittock SJ , et al. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol 2014; 35 (1) 84-89
  CrossrefPubMedGoogle Scholar
• 90 Pinheiro PS, Mulle C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci 2008; 9 (6) 423-436
  CrossrefPubMedGoogle Scholar
• 91 Benarroch EE. NMDA receptors: recent insights and clinical correlations. Neurology 2011; 76 (20) 1750-1757
  CrossrefPubMedGoogle Scholar
• 92 Dalmau J, Gleichman AJ, Hughes EG , et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7 (12) 1091-1098
  CrossrefPubMedGoogle Scholar
• 93 Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58 (4) 594-604
  CrossrefPubMedGoogle Scholar
• 94 McCoy B, Akiyama T, Widjaja E, Go C. Autoimmune limbic encephalitis as an emerging pediatric condition: case report and review of the literature. J Child Neurol 2011; 26 (2) 218-222
  CrossrefPubMedGoogle Scholar
• 95 Irani SR, Bera K, Waters P , et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133 (Pt 6) 1655-1667
  CrossrefPubMedGoogle Scholar
• 96 Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012; 79 (11) 1094-1100
  CrossrefPubMedGoogle Scholar
• 97 Hughes EG, Peng X, Gleichman AJ , et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30 (17) 5866-5875
  CrossrefPubMedGoogle Scholar
• 98 McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol 2009; 66 (6) 735-741
  CrossrefPubMedGoogle Scholar
• 99 Lennon VA, Kryzer TJ, Griesmann GE , et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995; 332 (22) 1467-1474
  CrossrefPubMedGoogle Scholar
• 100 Boronat A, Gelfand JM, Gresa-Arribas N , et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013; 73 (1) 120-128
  CrossrefPubMedGoogle Scholar
• 101 Tobin WO, Lennon VA, Komorowski L , et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 2014; 83 (20) 1797-1803
  CrossrefPubMedGoogle Scholar
• 102 Wada K, Yokotani N, Hunter C, Doi K, Wenthold RJ, Shimasaki S. Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family. Proc Natl Acad Sci U S A 1992; 89 (1) 197-201
  CrossrefPubMedGoogle Scholar
• 103 Nadal MS, Ozaita A, Amarillo Y , et al. The CD26-related dipeptidyl aminopeptidase-like protein DPPX is a critical component of neuronal A-type K+ channels. Neuron 2003; 37 (3) 449-461
  CrossrefPubMedGoogle Scholar
• 104 Titulaer MJ, McCracken L, Gabilondo I , et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12 (2) 157-165
  CrossrefPubMedGoogle Scholar
• 105 McKnight K, Jiang Y, Hart Y , et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005; 65 (11) 1730-1736
  CrossrefPubMedGoogle Scholar
• 106 McKeon A, Lennon VA, Pittock SJ. Immunotherapy-responsive dementias and encephalopathies. Continuum (Minneap Minn) 2010; 16 (2 Dementia): 80-101
  PubMedGoogle Scholar
• 107 McKeon A, Apiwattanakul M, Lachance DH , et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol 2010; 67 (3) 322-329
  CrossrefPubMedGoogle Scholar
• 108 Hacohen Y, Deiva K, Pettingill P , et al. N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 2014; 29 (1) 90-96
  CrossrefPubMedGoogle Scholar